Publications

Publications

To contact an EPI-Q author, please contact us.

Year  Author(s)TitleJournal / MeetingIndication / Keyword
2016Katz NP, Gajria KL, Shillington AC, Stephenson JL, Harshaw QImpact of breakthrough pain on community-dwelling cancer patients: results from the National Breakthrough Pain StudyPostgraduate MedicineOncology, Pain Management
2016Supina D, Herman BK, Frye CB, Shillington ACKnowledge of binge eating disorder: a cross-sectional survey of physicians in the United StatesPostgraduate MedicinePsychiatry, National Survey
2016Velez FF, Carter JA, Ettinger ABComparing anti-epileptic drug preferences between neurologists and patients: Results from a national survey and discrete choice experiment68th American Academy of Neurology Annual Meeting, April 15–21 2016, Vancouver, BC, CanadaEpilepsy, Discrete Choice Experiment
2016Bailey RA, Pfeifer M, Shillington AC, Harshaw Q, Funnell MM, VanWingen J, Col NEffect of a patient decision aid (PDA) for type 2 diabetes on knowledge, decisional self-efficacy, and decisional conflictBMC Health Services ResearchDiabetes, Patient Decision Aid, Shared Decision Making
2016Ganguli A, Clewell J, Shillington ACThe impact of patient support programs on adherence, clinical, humanistic, and economic patient outcomes: a targeted systematic reviewPatient Preference and AdherencePatient Support Program, Systematic Literature Review
2016Frost M, Dammerman R, Carter JA, Chen M, Ling WSubdermal buprenorphine implants improve societal outcomes and patient morbidity and mortality relative to sublingual buprenorphine: Results of a Markov modelAMCP Annual Meeting, April 19-22, 2016, San Francisco, CA, USAOpioid Dependence, Modeling
2016Rao S, Macahilig CP, Wolthoff P, Harshaw Q, Shillington ATwo-year advanced melanoma survival in treatment naïve subjects initiated with first-line lpilimumab 3mg/kg therapy: Evidence from a US multisite retrospective chart reviewNational Comprehensive Cancer Network 21st Annual Conference; March 21-April 2, 2016; Hollywood, FL, USAOncology, Chart Review
2015Davidson JA, Rosales A, Shillington AC, Bailey RA, Kabir C, Umpierrez GEImproving access to shared decision-making for Hispanics/Latinos with inadequately controlled type 2 diabetes mellitusPatient Preference and AdherenceDiabetes, Patient Decision Aid, Shared Decision Making, Cultural and Language Adaptation
2015Narayana A, Katz N, Shillington AC, Stephenson JJ, Harshaw Q, Frye CB, Portenoy RK.The National Breakthrough Pain Study: Prevalence, characteristics, and associations with health outcomesPainNeurology, Public Health, Outcomes Research
2015Trosch RM, Shillington AC, English ML, Marchese DA retrospective, single-center comparative cost analysis of OnabotulinumtoxinA and AbobotulinumtoxinA for cervical dystonia treatmentJ Manag Care Spec PharmChronic Pain, Economic Evaluation
2015Shillington AC, Col N, Bailey RA, Jewell MADevelopment of a patient decision aid for type 2 diabetes mellitus for patients not achieving glycemic control on metformin alonePatient Preference and AdherencePatient Decision Aid, Shared Decision-Making, Type 2 Diabetes
2015Davidson JA, Rosales A, Shillington AC, Bailey RA, Kabir C, Umpierrez GEImproving access to shared decision-making for Hispanics/Latinos with inadequately controlled type 2 diabetes mellitusPatient Preference and AdherenceDiabetes, Shared Decision-Making
2014Trosch RM, English ML, Shillington AC, Marchese DThe Dysport Economic Evaluation Program (DEEP): A Cost Analysis of Cervical Dystonia (CD) Treatment Switch from onabotulinumtoxinA (Botox [ONA]) to abobotulinumtoxinA (Dysport [ABO])International Parkinson and Movement Disorder Society, 18th International Congress of Parkinson's Disease and Movement Disorders, Stockholm, Sweden, June 8-12, 2014.Neurology, Economic Comparison
2014Trosch RM, English ML, Shillington AC, Marchese DThe AbobotulinumtoxinA Economic Evaluation Program (DEEP): A Cost Analysis Of Cervical Dystonia (CD) Treatment Switch From OnabotulinumtoxinA (Botulinum Toxin A [ONA]) To AbobotulinumtoxinA ([ABO])Movement Disorders Neurosciences
2014Davidson J, Allende-Vigo M, Aguilar R, Bailey R, Martin S, Shillington ACImproving Access to Shared Decision Making for Latin Americans with Inadequately Controlled Type 2 Diabetes MellitusAACE 23rd Annual Scientific & Clinical Congress – May 14-18, 2014 – Las Vegas, NevadaEndocrinology, Shared Decision Making
2014Shillington AC, Col N, Bailey RA, Martin SShared Decision-Making and a Patient Decision Aid for Inadequately Controlled Type 2 Diabetes MellitusAmerican Association of Diabetes Educators Annual Meeting – 2014, Orlando, Florida August 6–9th, 2014Endocrinology, Shared Decision Making
2014Aguilar R, Davidson J, Allende-Vigo M, Bailey R, Shillington, ACultural Adaptation of a Patient Decision Aid for Inadequately Controlled Type 2 Diabetes Mellitus in LatinosNational Hispanic Medical Association Meeting 18th Annual Conference – March 28-30, 2014 – Washington DCEndocrinology, Shared Decision Making
2013Roth T, Berglund P, Shahly V, Shillington AC, Stephenson JJ, Kessler RC.Middle-of-the-night hypnotic use in a large national health planJ Clin Sleep MedNeurosciences, Insomnia, Survey Research
2013Shahly V, Berglund PA, Coulouvrat C, Fitzgerald T, Hajak G, Roth T, Shillington AC, Stephenson JJ, Walsh JK, Kessler RCThe Associations of Insomnia with Costly Workplace Accidents and Errors: Results from the American Insomnia SurveyNational Sleep Foundation: Sleep Health & Safety 2013Neurosciences, Insomnia, Economic Analysis, Survey Research
2013Schechter LN, Harshaw Q, Ernst FR, Krukas MR, Shillington ACCosts Associated with Intravenous Patient Controlled Analgesia (IV PCA) in US HospitalsISPOR 18th Annual Int'l MeetingPost-op Pain
2013Rao S, Cifaldi M, Joshi AD, Shillington A, McGuire M, Wittig B, Rudwaleit MPrevalence Estimates of Axial Spondyloarthritis Among Patients in German Rheumatology PracticesAnn Rheum Dis Spondyloarthritis, Rheumatology
2013Kessler RC, Berglund PA, Coulouvrat C, Fitzgerald T, Hajak G, Roth T, Shahly V, Shillington AC, Stephenson JJ, Walsh JKInsomnia, Cormorbidity, and Risk of Injury Among Insured Americans: Results from the America Insomnia SurveyNational Sleep Foundation: Sleep Health & Safety 2013Neurosciences, Insomnia, Patient-Reported Outcomes, Survey Research
2013Narayana A, Katz N, Shillington AC, Stephenson JJ, Frye C, Portenoy REffect of Breakthrough Pain on Functional Status, Pain Interference, and Disability in Cancer Patients: Findings from the National Breakthrough Pain SurveyAmerican Society of Clinical Oncology (ASCO) Annual Meeting
J Clin Oncol (Meeting Abstracts) May 2013;31(15_suppl 6627).
Chronic Pain, Cancer Pain
2013Narayana A, Katz N, Shillington AC, Stephenson JJ, Frye C, White RE, Portenoy RBreakthrough Pain and Its Association with Functional Status, Pain Interference, and Disability in Cancer Patients: Findings from the National Breakthrough Pain StudyPAINWeek
Chronic Pain, Cancer Pain
2013Strand V, Rao SA, Shillington AC, Cifaldi MA, McGuire M, Ruderman EMPrevalence of Axial SpA in US Rheumatology Practices: Assessment of ASAS Criteria vs. Rheumatology Expert Clinical DiagnosisArthritis Care Res (Hoboken)Spondyloarthritis, Rheumatology
2013Narayana A, Katz N, Shillington AC, Stephenson JJ, Frye C, Portenoy RCosts Associated With Breakthrough Pain in Cancer Patients: Findings From the National Breakthrough Pain SurveyISPOR 18th Annual Int'l MeetingChronic Pain, Cancer Pain
2013Narayana A, Katz N, Shillington AC, Stephenson JJ, Frye C, White RE, Portenoy RCosts Associated with Breakthrough Pain in Cancer PatientsAmerican Academy of Pain ManagementChronic Pain, Cancer Pain
2013Kessler RC, Calabrese JR, Farley PA, Gruber MJ, Jewell MA, Katon W, Keck PE, Nierenberg AA, Sampson NA, Shear MK, Shillington AS, Stein MB, Thase ME, Wittchen HUComposite International Diagnostic Interview Screening Scales for DSM-IV Anxiety and Mood DisordersPsychol MedNeurosciences, Psychiatry, Screening Tool, Patient-reported Outcomes
2012Kessler RC, Berglund PA, Coulouvrat C, Fitzgerald T, Hajak G, Roth T, Shahly V, Shillington AC, Stephenson JJ, Walsh JKInsomnia, comorbidity, and risk of injury among insured Americans: results from the America Insomnia SurveySleepNeurosciences, Insomnia, Patient-Reported Outcomes, Survey Research
2012Kantarjian HK, Larson, RA, Cortes JE, Deering KL, Mauro MJCurrent Practices in the Management of Chronic Myeloid LeukemiaClin Lymphoma Myeloma LeukOncology, KABP Survey, Practice Patterns
2012Narayana A, Katz N, Shillington A, Stephenson J, Portenoy RThe National Breakthrough Pain Survey: Multivariate Predictors of Functional Status, Pain Interference, and DisabilityPAINWeekChronic Pain, Cancer Pain
2012Peyrot M, Harshaw Q, Shillington AC, Xu Y, Rubin RRValidation of a Tool to Assess Medication Treatment Satisfaction in Patients with Type 2 Diabetes: the Diabetes Medication System Rating Questionnaire (DMSRQ)Diabet MedDiabetes
2012Narayana A, Katz N, Shillington A, Stephenson J, Portenoy RThe Cost Associated with Breakthrough Pain: Findings from the National Breakthrough Pain SurveyPAINWeekChronic Pain, Cancer Pain
2012Shahly V, Berglund PA, Coulouvrat C, Fitzgerald T, Hajak G, Roth T, Shillington AC, Stephenson JJ, Walsh JK, Kessler RCThe Associations of Insomnia with Costly Workplace Accidents and Errors: Results from the America Insomnia SurveyArch Gen PsychiatryNeurosciences, Insomnia, Economic Analysis, Survey Research
2012Rao S, Shillington AC, Strand V, McGuire M, Cifaldi MAPrevalence Estimate and Gender Distribution of Axial Spondyloarthritis Among Patients in US Rheumatology PracticesAnnual European Congress of Rheumatology EULAR 2012Spondyloarthritis, Rheumatology
2012Berger, JS, Herout PM, Harshaw Q, Steinhubl SR, Frye CB, Becker RCBleeding-associated Outcomes with Preoperative Clopidogrel Use in On- and Off-pump Coronary Artery BypassJ Thrombosis and ThrombolysisCardiology, Antiplatelet Agents, Acute Coronary Syndrome, Pharmacoepidemiology Study
2011Roth T, Coulouvrat C, Hajak G, Lakoma MD, Sampson NA, Shahly V, Shillington AC, Stephenson JJ, Walsh JK, Kessler RCPrevalence and perceived health associated with insomnia based on DSM-IV-TR; International Statistical Classification of Diseases and Related Health Problems, Tenth Revision; and Research Diagnostic Criteria/International Classification of Sleep Disorders, Second Edition criteria: results from the America Insomnia SurveyBiol PsychiatryNeurosciences, Insomnia, Patient-Reported Outcomes, Survey Research
2011Hajak G, Petukhova M, Lakoma M, Coulouvrat C, Roth T, Sampson N, Shahly V, Shillington A, Stephenson J, Walsh J, Kessler RCDays-out-of-role associated with insomnia and comorbid conditions in the America Insomnia SurveyBiol PsychiatryNeurosciences, Insomnia, Patient-Reported Outcomes, Survey Research
2011Costello K, Foley J, Miller D, Deering KImplementation of a Web-Based Patient-Reported Outcomes Research ProgramAmerican Academy of NeurologyNeurology, Central Nervous System, Multiple Sclerosis, Patient-Reported Outcomes
2011Deering K, Agarwal S, Rajagopalan K, Harshaw Q, Shillington A, and the My MS Health Steering CommitteeCreation of a Web-Based Multiple Sclerosis Patient-Reported Outcomes Research ProgramValue in HealthNeurology, Central Nervous System, Multiple Sclerosis, Patient-Reported Outcomes
2010Kessler R, Coulouvrat C, Hajak GThe American Insomnia Survey: an epidemiology study of insomnia prevalence and burden in a representative populationISPOR 15th Annual Int'l MeetingNeurosciences, Insomnia, Patient-Reported Outcomes, Economic Analysis, Survey Research
2010Sterz R, Frye C, Harshaw QParicalcitol treatment in CKD patients with secondary hyperparathyroidism is associated with better health outcomes when compared with no vitamin D receptor [VDR] activator treatmentNational Kidney FoundationNephrology, Chronic Kidney Disease, Database Analysis
2010Marx S, Frye C, Khan SDialysis health outcomes associated with pre-dialysis use of paricalcitol compared with no vitamin D receptor (VDR) activator treatmentNational Kidney FoundationNephrology, Dialysis, Database Analysis
2010Kessker R, Farley A, Jewell MConcordance of computerized self-report measures of DSM-IV-Tr, mood and anxiety disorders compared to gold standard clinical assessments in primary careISPOR 15th Annual Int'l MeetingNeurosciences, Psychiatry, Screening Tool, Patient-Reported Outcomes
2010Kessler RC, Green JG, Adler LA, Barkley RA, Chatterji S, Faraone SV, Finkelman M, Greenhill LL, Gruber MJ, Jewell M, Russo LJ, Sampson NA, Van Brunt DLStructure and Diagnosis of Adult Attention-Deficit/Hyperactivity Disorder: Analysis of Expanded Symptom Criteria from the Adult ADHD Clinical Diagnostic ScaleArch Gen PsychiatryNeurosciences, Psychiatry
2010Kessler R, Hajak G, Lakoma MConcordance of self-report measures of DSM-IV-TR, ICD-10, and RDC insomnia with standardized clinical assessments in the American Insomnia Survey (AIS)ISPOR 15th Annual Int'l MeetingNeurosciences, Insomnia, Patient-Reported Outcomes
2010Marx S, Frye C, Khan S, Harshaw Q, Audhya P, Deering K, Sterz RImproved Resource Utilization Outcomes Associated with Predialysis Use of Paricalcitol for Secondary Hyperparathyroidism (SHPT)International Society of Pharmacoeconomics and Outcomes Research (ISPOR) Annual Meeting Poster PresentationNephrology, Dialysis, Database Analysis, Economic Analysis
2010Herout P, Harshaw Q, Phatak H, Saka G, McNeill A, Wu D, Sazonov V, DeSagun R, Shirani JImpact of Worsening Renal Function During Hospital Admission on Resource Utilization in Patients With Heart FailureAm J Cardiol Cardiology, Nephrology, Database Analysis, Economic
2010Bradley S. Miller, Dorothy I. Shulman, Alicia Shillington, et al.,Consensus and Discordance in the Management of Growth Hormone-Treated Patients: Results of a Knowledge, Attitudes, Beliefs, and Practices SurveyInt J Pediatr Endocrinol. 2010;2010:891571Endocrinology, Pediatric, KABP, Survey
2010Marx S, Frye C, Khan S, Harshaw Q, Audhya P, Deering K, Sterz RComparative Effectiveness of Paricalcitol Versus Calcitriol Treatment in Chronic Kidney Disease [CKD] Patients with Secondary Hyperparathyroidism [SHPT]National Kidney Foundation Spring Clinical Meeting Poster Presentation, Orlando, FL, April 13-15, 2010Nephrology, Dialysis, Database Analysis, Effectiveness Research
2010Narayana A, Katz N, Shillington AThe National Breakthrough Pain Survey (NBTPS): Design, Methodology, and Interim ResultsInternational Assoc. for the Study of Pain (IASP) 13th World Congress on PainPain, Neurosciences, Patient-Reported Outcomes, , Economic Analysis, Survey Research
2010Kessler R, Coulouvrat C, Hajak G, Lakoma MD, Roth T, Sampson N, Shahly V, Shillington A, Stephenson JJ, Walsh J, Zammit GKReliability and Validity of the Brief Insomnia Questionnaire (BIQ) in the America Insomnia Survey (AIS)SleepNeurosciences, Insomnia, Patient-Reported Outcomes, Survey Research
2009Cooper M, Deering KL, Slakey DP, Harshaw Q, Arcona S, McCann EL, Rasetto FA, Florman SS Comparing Outcomes Associated With Dose Manipulations of Enteric-Coated Mycophenolate Sodium Versus Mycophenolate Mofetil in Renal Transplant Recipients.?Transplantation Nephrology, Transplant, Immunosuppression, Effectiveness Research
2009Silverman R, Reibman J, and the New York State Asthma Control and Co-morbidities Working GroupPoorly Controlled Asthma and Health Service Utilization in New York in a Medicaid Managed Care Population.American Thoracic Society, San Diego, California, May 15-20, 2009. Poster #F33Pulmonology, Asthma, COPD, Medicaid, Database Analysis, Economic Analysis
2009Kessler RC, Coulouvrat C, Hajak G, Roth T, Sampson N, Shillington AC, Stephenson JJ, Walsh J.The American Insomnia Survey: an epidemiology study of insomnia in subjects with various comorbidities and/or conditions3rd International Congress on Sleep Medicine of the World Association of Sleep Medicine and the 12th Brazilian Congress on Sleep Medicine, Sao Paulo, Brazil, November 9-11, 2009. Abstract ID number 0812.Neurosciences, Insomnia, Patient-Reported Outcomes, Epidemiology Study, Survey Research
2009Frye CB, Andress DL, Marx SE, Harshaw Q, Sterz R, Deering K, Audhya PImpact of Pre-Dialysis Use of Calcitriol on Healthcare Resources Utilization and Costs Compared with No Vitamin D Receptor Activator (VDRA) Treatment for Secondary Hyperparathyroidism (SHPT)American Society of Nephrology?s Renal Week, San Diego, California, October 29, 2009. Poster #TH-PO660.Nephrology, Chronic Kidney Disease, Database Analysis, Economic Analysis
2009Marx SE, Frye CB, Andress DL, Harshaw Q, Sterz R, Deering K, Audhya PAll-Cause and Cardiovascular-Related Healthcare Resource Utilization and Costs Associated with Paricalcitol Use in Pre-Dialysis Chronic Kidney Disease (CKD) Patients with Secondary Hyperparathyroidism (SHPT) Compared with No Vitamin D Receptor Activator (VDRA) Therapy.American Society of Nephrology?s Renal Week, San Diego, California, October 29, 2009. Poster #TH-PO657.Nephrology, Chronic Kidney Disease, Database Analysis, Economic Analysis
2009Harshaw Q, Frye CB, Hauch O.?A Conceptual Analysis of the Costs of Care for a ?Major Bleed? in Studies of Antiplatelet and Antithrombotic Therapies.ISPOR 14th Annual International Meeting, Orlando, Florida, May 16-20, 2009. Abstract # 22426Cardiology, Antiplatelet Agents, Acute Coronary Syndrome
2009Harshaw Q, Andress DL, Marx SE, Frye CB, Sterz R, Deering K, Audhya PEvaluation of Pre-Dialysis Doxercalciferol Use on Health Outcomes and Costs Compared to No Vitamin D Receptor Activator (VDRA) Treatment for Secondary Hyperparathyroidism (SHPT)American Society of Nephrology?s Renal Week, San Diego, California, October 29, 2009. Poster #TH-PO661.Nephrology, Chronic Kidney Disease, Database Analysis, Economic Analysis
2009Jewell M, Keck P, Golden WE, Brewster C, Farley AP, Harshaw, Q. Discrepancies Between Knowledge, Attitudes and Beliefs and the Actual Practice (KABP) of Physicians who Care for Patients with Depression and/or Bipolar Disorder.ISPOR 14th Annual International Meeting, Orlando, Florida, May 16-20, 2009. Poster # PMH73Psychiatry, Neurosciences, Depression, Bipolar Disease
2009Kennedy J, Shulman D,Shillington A, Harshaw Q,Colgan K, Schwartz D, Kappy M, Wyatt D,Miller BS, Wilson D, McCormack L, Bakker B, Lippe BImproving data entry for post-marketing surveillance rhGH databases: Lessons from a knowledge (K), attitudes (A), beliefs (B) and practices (P) survey of Pediatric EndocrinologistsPediatric Endocrinology Nursing Society (PENS), 2009 Newport, RI, April 1-4, 2009Endocrinology, Growth Hormone, Registries
2008Gathe JC Jr.Switching HIV-infected, suppressed patients from ABC/3TC to FTC/TDF improves lipids - the SETTLE study.10th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, London, United Kingdom, November 6 to 8, 2008.Infectious Disease, Endocrinology, HIV/AIDS, Lipid Disorders
2008Pickard AS, Becker RC, Schumock GT, Frye CBClopidogrel-associated bleeding and related complications in patients undergoing coronary artery bypass grafting.PharmacotherapyCardiology, Antiplatelet Agents, Acute Coronary Syndrome, Pharmacoepidemiology Study
2008Miller BS, Shulman D, Shillington AC, et al. Consensus and discordance in treating recombinant human growth hormone (rhGH) treated patients: results of a knowledge (K), attitudes (A), beliefs (B) and practices (P) [KABP] survey.Pediatric Academic Societies & Asian Society for Pediatric Research Joint Meeting, Honolulu, Hawaii, May 2-6, 2008Endocrinology, Growth Hormone, Registries, KABP Survey
2008Brewster COverview of the STAndards for BipoLar Excellence (STABLE) Project.J Psychiatr PractPsychiatry, Neurosciences, Depression, Bipolar Disease, Quality Improvement, Performance Measures
2008Jewell MA, Golden W, Keck P et al.The STAndards for BipoLar Excellence (STABLE) Project: A bipolar disease quality improvement initiative to develop and validate evidence-based performance measures for national endorsement.13th Annual Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Toronto, Canada, May 5, 2008Psychiatry, Neurosciences, Depression, Bipolar Disease, Quality Improvement, Performance Measures
2008Stotland NL, Mattson MG, Bergeson S. The Recovery Concept: Clinician and Consumer Perspectives.J Psychiatr PractPsychiatry, Neurosciences, Depression, Bipolar Disease
2008Sachs GSPsychosocial Interventions as Adjunctive Therapy for Bipolar Disorder.J Psychiatr PractPsychiatry, Neurosciences, Depression, Bipolar Disease
2008Gathe Jr. JC, Yeh RF, Mayberry C, Nemecek J, Miguel B, Lipman BA, Fath MJSingle Agent Therapy with Lopinavir/Ritonavir Suppresses HIV-1 Viral Replication in ARV Na?ve Patients: IMANI II ? 96 Week Final Results.48th Annual ICAAC / IDSA 46th Annual Meeting, Washington D.C., October 25-28, 2008. Abstract H-1241Infectious Disease, HIV/AIDS, Phase III Study
2008Keck PE, Jr. Kessler RC, Ross RClinical and Economic Effects of Unrecognized or Inadequately Treated Bipolar Disorder.J Psychiatr PractPsychiatry, Neurosciences, Depression, Bipolar Disease, Quality Improvement, Economic Analysis
2008Berger JS, Frye CB, Harshaw Q, Edwards FH, Steinhubl SR, Becker RCImpact of clopidogrel in patients with acute coronary syndromes requiring coronary artery bypass surgery: a multicenter analysis.J Am Coll CardiolCardiology, Antiplatelet Agents, Acute Coronary Syndrome, Comparative Effectiveness
2008Williams JW, Jr., Manning JSCollaborative Mental Health and Primary Care for Bipolar Disorder.J Psychiatr PractPsychiatry, Neurosciences, Depression, Bipolar Disease
2008Golden WE, Keck PE, Jr., Sachs GS, Oldham JM, Brewster C, Ross RThe STABLE Project: Addressing the Gap Between Evidence and Practice for Bipolar Disorder.J Psychiatr PractPsychiatry, Neurosciences, Depression, Bipolar Disease, KABP Survey
2008Harshaw Q, Wygant GD, Hauch O, Berger JS, Frye CB, Becker RCPharmacoeconomic analysis of bleeding complications and reoperation costs in patients with ACS receiving clopidogrel who require CABG surgery.AHA 9th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke, Baltimore, Maryland, May 1-2, 2008Cardiology, Antiplatelet Agents, Acute Coronary Syndrome, Pharmacoeconomics
2008Berger JS, Frye CB, Harshaw Q, Edwards FH, Steinhubl SR, Becker RCImpact of thienopyridines on bleeding complications with ACS patients requiring CABG surgery.Scientific Sessions, 2007, American Heart Association (AHA), Orlando, Florida, November 4-7, 2007. (Abstract #8663, Presentation #3221). Midwest AHA Affiliate, Chicago, Illinois, November 19, 2007. American College of Clinical Pharmacy, Phoenix, Arizona, April 7, 2008Cardiology, Antiplatelet Agents, Acute Coronary Syndrome, Pharmacoepidemiology Study
2008Golden WE, Hermann RC, Jewell M, Brewster CDevelopment of Evidence-Based Performance Measures for Bipolar Disorder: Overview of Methodology.J Psychiatr PractPsychiatry, Neurosciences, Depression, Bipolar Disease. Performance Measures
2008Oldham JM, Golden WE, Rosof BM. Quality Improvement in Psychiatry: Why Measures Matter.J Psychiatr PractPsychiatry, Neurosciences, Depression, Bipolar Disease, Performance Measures
2007Patel B, Sheridan P, Detjen P, et al. Success of a Comprehensive school-based asthma intervention on clinical markers and resource utilization for inner-city children with asthma in Chicago: the Mobile C.A.R.E. Foundation's asthma management program.Journal of AsthmaAsthma, Pediatrics, Disease Management
2007Williams JW, Golden W, Keck PE, Jewel M, Brewster CPerformance indicators for bipolar disorder: development and feasibility testing.30th Annual Meeting of the Society of General Internal Medicine (SGIM), Toronto, Canada, April 2007.Psychiatry, Neurosciences, Depression, Bipolar Disease
2007Lustig R, Meacham L, Frane J, Frye C, Bakker BLinear growth and BMI during growth hormone treatment of children with craniopharyngioma compared to other organic growth hormone deficiencies: The National Cooperative Growth Study experience.46th Annual Meeting of the European Society for Paediatric Endocrinology, Helsinki, Finland, June 27-30, 2007. (Poster # PO2-489) Endocrinology, Growth Hormone, Registries,Craniopharyngioma
2007Rawlings MK, McGhee TA, Casey-Bailey S, Pasley MA comparison of adverse events and quality of life before and after switching from Kaletra? Soft-gel to Kaletra? Tablets in an African American cohort.American Conference for the Treatment of HIV (ACTHIV), Dallas, Texas, May 31-June 3, 2007. (Poster #82)Infectious Disease, HIV/AIDS
2007Gathe Jr. JC, Yeh RF, Mayberry C, et al. Single-agent Therapy with Lopinavir/ritonavir Suppresses Plasma HIV-1 Viral Replication in HIV-1 Na?ve Subjects: IMANI-2 48-Week Results.4th IAS Conference, Sydney, Australia. 22-25 July 2007. Poster # WEPEB034Infectious Disease, HIV/AIDS
2007Yeh, RF, Letendre S, Novak IS, et al. Single agent therapy with lopinavir/ritonavir controls HIV-1 replication in the central nervous system.14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, California, February 2007. (Poster 381)Infectious Disease, Neurosciences, HIV/AIDS
2006Gathe Jr. JC, Lipman BA, Mayberry C, Miguel B, Nemecek JTolerability and therapy preference of lopinavir/ritonavir (Kaletra) Soft-gel capsules and tablets as single agent in a cohort of HIV positive adult patients (IMANI-2).8th International Congress on Drug Therapy in HIV Infection, Glasgow, UK, November 2006. (Poster # P62)Infectious Disease, HIV/AIDS
2005Waldo AL, Becker RC, Tapson VF, Colgan KJHospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation.Journal of the American College of CardiologyCardiology, Atrial Fibrillation, Stroke, Anticoagulants
2005Watson JT. Jones RC. Siston AM. Fernandez JR. Martin K. Beck E. Sokalski S. Jensen BJ. Arduino MJ. Srinivasan A. Gerber SIOutbreak of catheter-associated Klebsiella oxytoca and Enterobacter cloacae bloodstream infections in an oncology chemotherapy center.Archives of Internal MedicineInfectious Disease, Oncology, Sepsis
2005Tapson VF, Hyers TM, Waldo AL, et al.Antithrombotic therapy practices in US hospitals in an era of practice guidelines.Archives of Internal MedicineCardiology, Anticoagulants, Antithrombotics
2005Shillington AC, Farley PA, Varkey JA, Dempsey C, Murdakes CRetrospective cohort study of granisetron administration for PONV prophylaxis and treatment.Hospital PharmacyPost-Operative Nausea and Vomiting
2005Caprini JA, Tapson VF, Hyers TM, et al. Treatment of venous thromboembolism: adherence to guidelines and impact of physician knowledge, attitudes, and beliefs.Journal of Vascular SurgeryCardiology, Venous Thromboembolism, Guidelines, Anticoagulants
2004Porter JA, Raebel MA, Conner DA, et alThe Long-term Outcomes of Sibutramine Effectiveness on Weight (LOSE Weight) Study: evaluating the role of drug therapy within a weight management program in a group-model health maintenance organization.Am J Manag CareObesity and Weight Loss
2004Sharif A, Ajlouni M, Wollner I, et al.Oral capecitabine plus radiation therapy administered neoadjuvantly in the management of rectal cancer.86th Annual Meeting of the American Radium Society (ARS), Napa Valley, California, May 2004Oncology, Rectal Cancer
2004Dempsey CL, Coop AJ, Shillington AC, Farley PA, Eberhardt DR, O?Briant SAntiemetic effectiveness of ondansetron and granisetron in patients with breast cancer treated with cyclophosphamide.American Journal of Health-System Pharmacy. 2004;61(8):781-786Oncology, Breast Cancer, Nausea and Vomiting Preventions
2004Rogers LR, Remer SE, Sheela Tejwani SDurable response of breast cancer leptomeningeal metastasis to capecitabine monotherapy: case report.Neuro-OncologyOncology, Breast Cancer
2004Tapson VF, Hyers TM, Becker RC, Waldo AL, Colgan KJ, Shillington AC. The National Anticoagulation Benchmark and Outcomes Report (NABOR?): evidence of a significant difference between guidelines and actual practice.International Society for Pharmacoeconomics and Outcomes Research 9th Annual International Meeting, Arlington, Virginia, May 2004Cardiology, Anticogulants, Antithrombotics
2004Jensen DM, Cotler SJ, Lam H, Harb G, Shillington ACA comparison of hepatitis C treatment and outcomes at academic, private and Veterans? Affairs treatment centers.Journal of Alimentary Pharmacology and TherapeuticsInfectious Disease, Hepatitis
2004Caprini JA, Marchev D, Glase C, et al. Venous thromboembolism treatment: results of a national database.American Venous Forum, Orlando, Florida, February 2004Cardiology, Anticogulants, Antithrombotics
2004Caprini JA, Ballard DJ, Becker RC, et al. Disparities in antithrombotic management.American Heart Association 5th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke, Washington DC, May 2004Cardiology, Anticogulants, Antithrombotics
2003Mortimer JE, Lauman MK, Tan B, Dempsey CL, Shillington AC, Hutchins KSPyridoxine treatment and prevention of hand-and-foot syndrome in patients receiving capecitabine.Journal of Oncology Pharmacy PracticeInfectious Disease, Hand-and-Foot Syndrome
2003El-Rayes, BF ,Black CA, Ensley JFHormone-refractory prostate cancer responding to capecitabineUrologyOncology, Prostate Cancer
2003Hampton N, Romie A, Clewell L, Hadzima S, Gerdes JM. Management of community-acquired pneumonia in one hospital compared with a national benchmark database.Hospital PharmacyInfectious Disease, Community-Acquired Pneumonia
2003Shillington A, Dempsey C, Farley PA, Coop A, Eberhardt DR, Varkey JAA descriptive practice evaluation of granisetron utilization in the management of postoperative nausea and vomiting.New York State Society of Anesthesia Annual Meeting, New York City, New York, December 2003Post-Operative Nausea and Vomiting
2003Duckworth W, Marcelli M, Padden M, et al. Improvements in glycemic control in type 2 diabetes patients switched from sulfonylurea coadministered with metformin to glyburide-metformin tablets.Journal of Managed Care PharmacyEndocrinology, Type 2 Diabetes
2003Hindenburg AA, Matthews LComplete and sustained remission of refractory cervical cancer following a single cycle of capecitabine. a case report.International Journal of Gynecological Cancer. 2003;13(6):898-900
Oncology, Cervical Cancer
2003Rich S, Shillington AC, McLaughlin VComparison of survival in patients with pulmonary hypertension associated with fenfluramine to patients with primary pulmonary hypertension.American Journal of CardiologyCardiology, Pulmonary Hypertension, Obesity and Weight Loss
2003Billeter M, Levato J, Waldrep T, Dempsey CL, Farley PAA multicenter drug utilization evaluation program for Timentin?.ASHP Midyear Meeting, New Orleans, Louisiana, December 2003. (P-644E)Infectious Disease, Medication Use Evaluation
2003Coop AJ, Farley PA, Shillington AC, Dempsey CL, Colgan KC5-HT3 antiemetic use in breast cancer patients receiving cyclophosphamide: a multi-center practice evaluation.MASCC/ISOO 15th International Symposium, Berlin, Germany, June 2003. (Poster 7)Oncology, Breast Cancer, Nausea and Vomiting Preventions
2002Vaishampayan UN, Ben-Josef E, Philip PA, et al.A single-institution experience with concurrent capecitabine and radiation therapy in gastrointestinal malignancies.Int J Radiation Oncology Biology PhysicsOncology, Infectious Disease
2002Tan M, Xu R, Seth RGranisetron vs. dolasetron for acute nausea and vomiting in high and moderately-high emetogenic chemotherapy.MASCC/ISOO 14th International Symposium, Boston, Massachusetts, June 2002. (Poster 117)Oncology, Chemotherapy-related Nausea and Vomiting
2002McLaughlin VV, Shillington A, Rich SSurvival in primary pulmonary hypertension: the impact of epoprostenol therapyCirculationCardiology, Pulmonary Hypertension
2002Rich S, Shillington A, McLaughlin VVPrognosis of patients with primary pulmonary hypertension induced by fenfluramine diet pills.American Thoracic Society, Atlanta, Georgia, May 2002. (Abstract 37, Poster B15)Cardiology, Pulmonary Hypertension, Obesity and Weight Loss
2002Duckworth W, Marcelli M, Roman F, et al.?Improvements in glycemic control in type 2 diabetes patients switched from sulfonylurea co-administered with metformin to glyburide/metformin tablets.Academy of Managed Care Pharmacy, Washington, DC, October 2002. (Poster PDR 13)Endocrinology, Type 2 Diabetes
2001Shillington AC, Dempsey CL, Colgan KJ, Farley PA, Jewell MAShifting low risk CAP to the outpatient setting: implications for treatment selection.ASHP Midyear Meeting, New Orleans, Louisiana, December 2001. (Abstract P682-E)Infectious Disease, Community-Acquired Pneumonia
2001Sokalski S, Jewell MA, Dempsey C, Shillington AEvaluation of use and outcomes of IDSA Guidelines in patients with community-acquired pneumonia at low mortality risk.Infectious Diseases Society of America, San Francisco, California, October 2001Infectious Disease, Community-Acquired Pneumonia
2001Jensen DM, Cotler SJ, Herb G, et al. Comparison of outcomes, treatment selection and completion in hepatitis C patients in academic and community based ambulatory treatment centers. AASLD Annual Meeting, Dallas, Texas, November 2001. (Abstract 404049)Infectious Disease, Hepatitis
2001Lonfield V, Hasan E, Romie A. A retrospective evaluation of the use of pyridoxine in the prevention and treatment of palmer-plantar erythrodysesthesia in capecitabine treated cancer patients.Oncology Nursing Society, August 2001Oncology
2001Romie AR, Aquayo S, Eagye K, Shillington A, Dempsey CAn evaluation of CAP management in the VA Healthcare System.ASHP Midyear Meeting, New Orleans, Louisiana, December 2001Infectious Disease, Community-Acquired Pneumonia
2001Romie AM, Dempsey CL, Shillington AC, Jewell MA, Farley PAEffectively treating pneumonia as an outpatient: implications for the managed care pharmacist.AMCP Annual Meeting, Philadelphia, PA, April 2001Infectious Disease, Pneumonia
2001Romie AM, Farley A, Teeters J, Jewell MAIntegrated system evaluation of CAP management.ASHP Midyear Meeting, New Orleans, Louisiana, December 2001. (Abstract P671-E)Infectious Disease, Community-Acquired Pneumonia
2001Weber M, Reno S, Hornbake R, Shillington AAn in-home Synagis program for RSV prevention in high-risk infants.Journal of Managed Care PharmacyInfectious Disease, Respiratory Syncytial Virus
2001Shillington AC, Hilley H, Carter WA, Strayer DRChronic fatigue syndrome (CFS): pharmacoeconomic analysis of Ampligen? intervention.AACSF Annual Meeting, Seattle, Washington, February 2001Chronic Fatigue syndrome
2000Hampton N, Hadzima S, Clewell L. Romie AM, Gerdes JSuccessful multidisciplinary implementation with electronic evaluation of community-acquired pneumonia.ASHP Midyear Meeting, Las Vegas, Nevada, December 2000. (Abstract P-285E)Infectious Disease, Community-Acquired Pneumonia
2000Mizell PL, Harris S. Moore LA, et alSuccessful implementation of a pneumonia outcomes management program in a large southeastern medical center.ASHP Annual Meeting, Philadelphia, Pennsylvania, June 2000. (Abstract P-47E)Infectious Disease, Pneumonia
2000Shillington ACOngoing issues in pneumonia care: when to admit, how to treat and the role of oral therapy. Journal of Medical SystemsInfectious Disease, Pneumonia
2000Seshadri V, Dempsey CL, Romie AM, Shillington AClarithromycin vs. routine treatment in intervenous to oral switch for community-acquired pneumonia: an evaluation in 41 United States hospitals.ASHP Annual Meeting, Philadelphia, Pennsylvania, June 2000. (Abstract P-42D)Infectious Disease, Community-Acquired Pneumonia
2000Colgan K, Moody ML, Witte KResponsible use of blood products in response to supply and demand.Am J Health-Syst PharmHematology, Blood Use
2000Romie AM, Colgan K, Berstein G, Seshadri V, Dempsey CLNational severity-adjusted benchmark outcomes program for community acquired pneumonia.ASHP Midyear Meeting, Las Vegas, Nevada, December 2000. (Abstract P-282EInfectious Disease, Community-Acquired Pneumonia
1999Dempsey CL, Shillington AC, Jewell MA, Farley PA, Goliak MKOptimizing management of hospitalized patients with community-acquired pneumonia.Infections in MedicineInfectious Disease, Community-Acquired Pneumonia
1999Carro G, Rough S, Dempsey CL, Shillington AC, Khandekar JDClinical strategies for oral 5-HT3 receptor antagonist therapy for the prevention of chemotherapy-induced nausea and vomiting.Pharmacy and TherapeuticsOncology, Chemotherapy-related Nausea and Vomiting
1999Moyers P, Ross J, Goliak MK, Seshadri V, Shillington ASuccessful intervenous-to-oral switch outcomes in the management of pneumonia in an integrated system.ASHP Midyear Meeting, Orlando, Florida, December 1999. (Abstract 34:P-121E)Infectious Disease, Pneumonia
1999Carro G, Khandekar J, Seshadri V, Farley PA, Dempsey CL, Goliak MKProspective implementation of evidence based outcome management for chemotherapy induced nausea and vomiting in an outpatient setting.ASHP Midyear Meeting, Orlando, Florida, December 1999. (Abstract P-103D)Oncology, Chemotherapy-related Nausea and Vomiting
1999Sokalski SJ, Shillington AC, Goliak M, et al. Benchmark evaluation of severity-adjusted outcomes and treatment associated with community acquired pneumonia.Infectious Disease Society of America, Philadelphia, Pennsylvania, November 1999Infectious Disease, Community-Acquired Pneumonia
1999Jewell MA, Dzelme A, Goliak MK, Dempsey CLDetermining cost effective treatment for pneumonia using the CAPPM software program for antibiotic selection.American Society of Heath Systems Pharmacists Annul Meeting, Reno, Nevada, June 1999. (CS-3)Infectious Disease, Community-Acquired Pneumonia
1999DeVoe MG, Broun ER, Sargent WK, Dempsey CL, Seshadri VClinical outcomes associated with the use of oral granisetron in bone marrow transplantation.ASHP Midyear Meeting, Orlando, Florida, December 1999. (Abstract P-462E)Transplant, Bone Marrow Transplant, Nausea and Vomiting
1999Mullner RM, Jewell MA, Mease MAMonitoring changes in home health care: a comparison of two national surveys.Journal of Medical SystemsAmbulatory and Nursing Home Care
1999Dempsey CL, Nicolau DP, Sokalski SJ, Shillington AC, Jewell MA, Goliak MKNursing home-acquired pneumonia: benchmarking treatment and outcomes in ten hospitals in the United States.Pharmacy & TherapeuticsInfectious Disease, Community-Acquired Pneumonia
1999Dempsey CL, Goliak MK, Seshadri V, Farley PA, Jewell MA, Shillington ACAggressive short-term admission for community acquired pneumonia in six large integrated health care delivery systems.American Society of Heath Systems Pharmacists Annual Meeting, Reno, Nevada June 1999. (Abstract P-24R)Infectious Disease, Community-Acquired Pneumonia
1998Dempsey CL, Shillington AC, Goliak MOral 5-HT3 receptor antagonists: expanding options for medicare outpatients.Journal of the American Pharmaceutical AssociationOncology, Chemotherapy-related Nausea and Vomiting
1998Ramirez J, Kemmerly S, Simonson D, Mandler HD, Shillington ACCost effective care for pneumonia: using the ACES software program for intravenous to oral switch.ASHP Midyear Clinical Meeting, Las Vegas, Nevada, December 1998. (Abstract P-445E)Infectious Disease, Pneumonia
1998Bhat G, Jordan Jr. J, Sokalski S, Bajaj V, Marshall R, Berkelhammer, CMinocycline-induced hepatitis with autoimmune features and neutropenia.Journal of Clinical GastroenterologyInfectious Disease, Therapeutics
1998Clark CD, Abel SR, Dempsey CL, Shillington AC, Byun MHCost analysis of ondansetron and granisetron in the management of chemotherapy induced nausea and vomiting.Hospital PharmacyOncology, Chemotherapy-related Nausea and Vomiting, Economic Analysis
1997Rough SS, Carro G, Dempsey CL, Shillington ACDeveloping and implementing oral 5HT3 receptor antagonist guidelines through a multidisciplinary process.ASHP Annual Meeting, Minneapolis, Minnesota, June 1997. (MCS-8)Oncology, Chemotherapy-related Nausea and Vomiting, Guideline Development
1997Dempsey CL, Shillington AC, Jewell MA, Farley PAEvaluation of nursing home acquired pneumonia treatment in the emergency departments of ten hospitals.ASHP Midyear Clinical Meeting, Atlanta, Georgia, December 1997. (Abstract P-385E)Infectious Disease, Nursing Home Acquired Pneumonia, Quality Improvement
1997Dempsey CL, Farley PA, Shillington AC, Cheff CMSelf reported assessment of functional status following 5-hydroxytryptamine 3 receptor antagonist therapy to chemotherapy induced nausea and vomiting in six cancer center.Association for Pharmacoeconomics and Outcomes Research, Philadelphia, Pennsylvania, April 1997Oncology, Chemotherapy-related Nausea and Vomiting, Patient-Reported Outcomes
1997Carro G, Rough SS, Dempsey CL, Shillington ACCost effective care using oral 5-HT3 receptor antagonists for preventing chemotherapy induced nausea and vomiting.ASHP Annual Meeting, Minneapolis, Minnesota, June 1997. (Abstract P-43E)Oncology, Chemotherapy-related Nausea and Vomiting, Economic Analysis
1997Harris EM, Shillington AC, Dempsey CL, Blackwell B, Farley PABenchmarking evaluation of 5-HT3-receptor antagonist use in emetogenic chemotherapy.Hospital FormularyOncology, Chemotherapy-related Nausea and Vomiting, Benchmarking Study
1997Farley PA, Dempsey CL, Shillington AC, Kulis-Robitaille C, Colgan KJ, Bernstein GPatients' self reported functional status after granisetron or ondansetron therapy to prevent chemotherapy-induced nausea and vomiting at six cancer centers.American Journal of Health Systems PharmacyOncology, Chemotherapy-related Nausea and Vomiting, Patient-Reported Outcomes
1996Sokalski SJ, Shillington AS, Jewell MA, Dempsey CLA multi-center benchmarking study to improve outcomes with pneumonia.The Infectious Disease Society of American Annual Meeting, New Orleans, Louisiana. September 1996Infectious Disease, Pneumonia, Benchmarking Study
1996Shillington AC, Dempsey CL, Farley PA, White RE, Harris E, Blackwell BRisk assessment model for chemotherapy induced nausea and vomiting: using outcomes management in designing prevention strategies.ASHP Annual Meeting, San Diego, California, June 1996. (P-70 R)Infectious Disease, Pneumonia, Quality Improvement
1996Dempsey CL, Shillington AC, Farley PA, Gelone S, Nicolau D, Robitaille CKDisease state management: development of a severity model for pneumonia.ASHP Annual Meeting, San Diego, California, June 1996. (P-34R)Infectious Disease, Pneumonia, Non-Interventional Studies
1996Dempsey CL, Sokalski, SJ, Shillington, AS, Jewell, MAA disease management study to improve outcomes associated with pneumonia.The Society for Medical Decision Making Annual Meeting, Toronto, Canada, October 1996Infectious Disease, Pneumonia, Non-Interventional Studies
1995Bernstein G, Colgan K, Martz C, et al. Quality of life assessment of patients receiving granisetron and ondansetron prior to and after chemotherapy.ASHP Midyear Clinical Meeting, December 1995. (P-46B)Oncology, Chemotherapy-related Nausea and Vomiting, Patient-Reported Outcomes
1995Dempsey CL, Nicolau DP, Wagley W, Shillington AC, Jewell MA, Farley PA. Disease state management model for pneumonia: a multi-center benchmark project.Internal Medicine Physicians, Chicago, Illinois, June and October 1995. ASHP Midyear Clinical Meeting, December 1995. (P-281E)Infectious Disease, Pneumonia, Benchmarking Study
1995Dempsey CL, Lewis GSPharmacoeconomics: overview and applications.The Journal of Pharmacy PracticePharmacoeconomics
1995Blackwell BG, Harris EM, Clark CD, et al. Disease state management model for chemotherapy induced nausea and vomiting: multi-center benchmark project.ASHP Midyear Clinical Meeting, December 1995. (P-195R)Oncology, Chemotherapy-related Nausea and Vomiting, Benchmarking Study
1995Jewell MAQuantitative methods for quality improvement.PharmacotherapyQuality Improvement
1995Dempsey CLNursing home-acquired pneumonia: outcomes from a clinical process improvement program.PharmacotherapyInfectious Disease, Nursing Home Acquired Pneumonia, Quality Improvement
1994Dempsey CLNew pharmaceutical agents: a therapeutic summary.Pharmacy TimesTherapeutics, Literature Review
1993Dempsey CL, Kaley TC, Zendel JDrug usage evaluation: clarithromycin as sequential therapy.Hospital FormularyInfection Disease, Therapeutics
1992Sokalski SJ, Jewell MA, Asmus-Shillington AC, Mulcahy J, Segreti JAn outbreak of serratia marcescens in 14 adult cardiac surgical patients associated with 12-lead electrocardiogram bulbs.Archives of Internal MedicineInfectious Disease, Epidemology Study
1990Fliegelman RM, Mattingly PM, Dempsey CL, Solkalski SJEconomic impact of oral ciprofloxacin following standard intravenous therapy.Diag Microbiol Infect DisInfectious Disease, Economic Analysis
1989Fligner DJ, Wigder HN, Harter PM, Fliegelman RM, Jewell M, Perlman PThe prevalence of hepatitis B serological markers in suburban paramedics.The Journal of Emergency MedicineInfectious Disease
1988Jewell M, Davis Z, Fliegelman R, Guillory J, Sokalski S. Infection following coronary artery surgery: comparison of two antibiotic prophylaxis regimens.ChestInfectious Disease, Comparative Effectiveness
Share